The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Therapeutic options in VEXAS syndrome: insights from a retrospective series
Abstract
Bourbon et al describe a series of 19 patients from France with VEXAS syndrome, including a novel genetic aberration in UBA1, and the outcomes of treatment for those with and those without myelodysplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
Beck, D. B., Ferrada, M. A., Sikora, K. A., Ombrello, A. K., Collins, J. C., Pei, W., Balanda, N., Ross, D. L., Ospina Cardona, D., Wu, Z., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026834 · Cited by 1,206
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Self-citationFraison, J. B., MEKINIAN, A., Grignano, É., Kahn, J., Arlet, J., Decaux, O., Denis, G., Buchdahl, A.-L., Omouri, M., Maigné, G., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.005 · Cited by 113
Cited by
Georgin‐Lavialle, S., Terrier, B., Guedon, A. F., Heiblig, M., Comont, T., Lazaro, E., Lacombe, V., Terriou, L., Ardois, S., Bouaziz, J. ‐., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20805 · Cited by 427
Self-citation
Metadata
- Authors
- Bourbon, E., Heiblig, M., Gerfaud Valentin, M., Barba, T., Durel, C.-A., Lega, J. C., Barraco, F., Sève, P., Jamilloux, Y., & Sujobert, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-02-22
- Volume
- 137
- Issue
- 26
- Pages
- 3682-3684
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3131395638
- Cited by
- 280
- References
- 6
- FWCI
- 29.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic options in VEXAS syndrome: insights from a retrospective series. https://app.cochat.ai/papers/10.1182/blood.2020010177
- The paper
- Bourbon, E., Heiblig, M., Gerfaud Valentin, M., Barba, T., Durel, C.-A., Lega, J. C., Barraco, F., Sève, P., Jamilloux, Y., & Sujobert, P. (2021). Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. https://doi.org/10.1182/blood.2020010177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.